<DOC>
	<DOCNO>NCT00086320</DOCNO>
	<brief_summary>The purpose study determine efficacy ( effectiveness ) safety paliperidone ER compare placebo prevention recurrence symptom schizophrenia .</brief_summary>
	<brief_title>A Study Effectiveness Safety Paliperidone Extended-release ( ER ) Tablets Prevention Recurrence Adult Patients With Schizophrenia .</brief_title>
	<detailed_description>Paliperidone ER currently investigate treatment acute symptom schizophrenia also maintenance treatment . This trial design evaluate efficacy safety paliperidone ER prevention recurrence psychotic symptom patient schizophrenia . This trial randomize ( patient assign different treatment group base solely chance ) , double-blind ( neither patient physician know placebo drug give dose ) , placebo-controlled , parallel-group , multicenter study consist 5 phase : screen phase 5 day ; 8-week open-label run-in phase , patient treat open-label , flexibly dose paliperidone ER ( 3 15 mg ) orally daily identify dose achieve control acute psychotic symptom ( patient maintain stable dosage regimen total Positive Negative Syndrome Scale [ PANSS ] score &lt; /=70 ; Clinical Global Impression Scale - Severity [ CGI-S ] &lt; /=4 ; score &lt; /=4 PANSS item delusion , conceptual disorganization , hallucinatory behavior , suspiciousness/persecution , hostility , uncooperativeness last 2 week run-in phase eligible continue stabilization phase ) ; 6-week open-label stabilization phase , patient maintain control acute psychotic symptom paliperidone ER dosage identify run-in phase meet total PANSS score , CGI-S , PANSS item score throughout stabilization phase randomize receive either flexibly dose paliperidone ER , start dose maintain stabilization phase study , placebo ; double-blind treatment phase variable duration , patient follow meet either define criterion recurrence study end ; 52-week open-label extension phase patient experience recurrence event double-blind phase study , remain recurrence free entire double-blind phase study . Efficacy assess use PANSS CGI-S score collect every week , every 2 week , every 4 week throughout . Safety assessment include incidence adverse event throughout study ; measurement vital sign ( orthostatic pulse rate , orthostatic blood pressure , temperature ) ; clinical laboratory test . In run-in , double-blind , open-label extension phase study , paliperidone ER match placebo flexibly dose range 3 15 mg orally day ( 3 , 6 , 9 , 12 , 15 mg/day ) . The dosage stabilization phase fix throughout dosage achieve symptom control run-in phase .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>DSMIV diagnosis schizophrenia least 1 year screen experience acute schizophrenic episode total PANSS score 70 120 agree hospitalize minimum 14 day start study capable administer study medication assistance study medication administration consistently available throughout study reside address continuously least 30 day prior screen able willing fill self administer questionnaire washout antiparkinsonian medication , betablockers antiepileptic , lithium 3 day prior start runin phase DSMIV Axis I diagnosis schizophrenia DSMIV diagnosis substance dependence within 6 month prior screen ( nicotine caffeine dependence exclusionary ) preexist severe gastrointestinal narrowing ( pathologic iatrogenic ) injection depot antipsychotic within 120 day screen , use paliperidone palmitate within 10 month screen previous history lack response risperidone acutely psychotic history neuroleptic malignant syndrome significant risk suicidal violent behavior</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>paliperidone</keyword>
	<keyword>Risperidone</keyword>
</DOC>